Novel donor-π-acceptor benzimidazole-based chromophores: synthesis, antitumor assessment, and pharmacokinetics
Abstract
= 12.19 ± 0.30 µM towards PC3 cells. Meanwhile, the four targeted chromophores were tested towards VEGFR-2 using the reference sorafenib, which is a noticeable target in anti-angiogenic cancer therapy. The docking results revealed that hybrid 4b exhibited the strongest binding score, which was close to that of sorafenib (reference), suggesting that it shows the most promising profile. Analysis by SwissADME revealed that hybrids 2a and 4a exhibited good pharmacokinetic properties, such as high gastrointestinal absorption and blood-brain barrier permeability. In conclusion, the combined experimental and computational approach presented here suggests the potential of these benzimidazole chromophores as early leads for anticancer and anti-angiogenic agents.
Fields of Study & Subjects
Nonlinear Optical Materials Research
Synthesis and biological activity
Multicomponent Synthesis of Heterocycles
Publication details
- Journal / source
- RSC Advances
- Publisher
- Royal Society of Chemistry (RSC)
- Volume
- 16
- Issue
- 15
- Pages
- 13644–13657
- Publication date
- 1 January 2026
- Language
- EN